Neurim Launches Phase 2 Trial to Test Sleep Therapy Piromelatine In Alzheimer’s Patients

Neurim Launches Phase 2 Trial to Test Sleep Therapy Piromelatine In Alzheimer’s Patients
Israel’s Neurim Pharmaceuticals is now recruiting up to 500 U.S. patients with mild Alzheimer’s disease for a Phase 2 trial to study the safety and efficacy of its experimental drug, piromelatine. Alzheimer’s is caused by the accumulation of faulty proteins that lead to the formation of beta-amyloid plaques, which greatly interfere with proper neuronal activity and eventually

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *